Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
Although the detailed pathogenesis of multiple sclerosis (MS) is not completely understood, a broad range of disease-modifying therapies (DMTs) are available. A common side effect of nearly every MS therapeutic agent is lymphopenia, which can be both beneficial and, in some cases, treatment-limiting...
Guardado en:
Autores principales: | Stefanie Fischer, Undine Proschmann, Katja Akgün, Tjalf Ziemssen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/773e4e5edb1145db9fb77154980f8385 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ESTRIOL IN FUNCTIONAL MODULATION OF REGULATORY LYMPHOCYTES IN MULTIPLE SCLEROSIS
por: I. V. Nekrasova, et al.
Publicado: (2014) -
Utility of total lymphocyte count as a surrogate for absolute CD4 count in the adult Indian HIV population: A prospective study
por: Suman S Karanth, et al.
Publicado: (2014) -
EVALUATION OF IMMUNOTOXICITY OF THE THERAPEUTIC DRUG PROLONGED ACTION FOR MULTIPLE SCLEROSIS ON RHESUS MONKEYS
por: A. B. Dzheliya, et al.
Publicado: (2015) -
Multiple sclerosis international
Publicado: (2010) -
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis
por: Tobias Moser, et al.
Publicado: (2021)